Copyright
©The Author(s) 2018.
World J Gastrointest Oncol. Nov 15, 2018; 10(11): 410-420
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.410
Published online Nov 15, 2018. doi: 10.4251/wjgo.v10.i11.410
All patients | RCC | LCC | ||||||
(n = 942) | (n = 456) | (n = 486) | ||||||
n | % | n | % | n | % | P | ||
Age (yr) | < 65 | 636 | 67.5 | 304 | 66.7 | 332 | 68.3 | 0.590 |
≥ 65 | 306 | 32.5 | 152 | 33.3 | 154 | 31.7 | ||
Gender | Male | 511 | 54.2 | 250 | 54.8 | 261 | 53.7 | 0.730 |
Female | 431 | 45.8 | 206 | 45.2 | 225 | 46.3 | ||
Family history | No | 916 | 97.2 | 439 | 96.3 | 477 | 98.1 | 0.790 |
Yes | 26 | 2.8 | 17 | 3.7 | 9 | 1.9 | ||
Smoking status | No | 592 | 62.8 | 277 | 60.7 | 315 | 64.8 | 0.192 |
Yes | 350 | 37.2 | 179 | 39.3 | 171 | 35.2 | ||
Alcohol use status | No | 893 | 94.8 | 434 | 95.2 | 459 | 94.4 | 0.614 |
Yes | 49 | 5.2 | 22 | 4.8 | 27 | 5.6 | ||
Mode of surgery | Elective | 791 | 84 | 400 | 87.7 | 391 | 80.5 | 0.002 |
Emergent | 151 | 16 | 56 | 12.3 | 95 | 19.5 | ||
DM | No | 845 | 89.7 | 407 | 89.3 | 438 | 90.1 | 0.527 |
Yes | 93 | 9.9 | 48 | 10.5 | 45 | 9.3 | ||
HT | No | 717 | 76.1 | 344 | 75.4 | 373 | 76.7 | 0.329 |
Yes | 223 | 23.7 | 112 | 24.6 | 111 | 22.8 | ||
Histology | Adenocarcinoma | 779 | 82.7 | 356 | 78.1 | 423 | 87 | < 0.001 |
Mucinous adenocarcinoma | 163 | 17.3 | 100 | 21.9 | 63 | 13 | ||
Tumor grade | Well and moderately | 879 | 93.3 | 420 | 92.1 | 459 | 94.4 | 0.151 |
Poorly | 63 | 6.7 | 36 | 7.9 | 27 | 5.6 | ||
Tumor stage | II | 567 | 60.2 | 271 | 59.4 | 296 | 60.9 | 0.644 |
III | 375 | 39.8 | 185 | 40.6 | 190 | 39.1 | ||
pT stage | T1-2 | 133 | 14.1 | 57 | 12.5 | 76 | 15.6 | 0.267 |
T3 | 752 | 79.8 | 374 | 82 | 378 | 77.8 | ||
T4 | 57 | 6.1 | 25 | 5.5 | 32 | 6.6 | ||
The number of removed lymph nodes | < 12 | 296 | 31.4 | 102 | 22.4 | 194 | 39.9 | < 0.001 |
≥ 12 | 646 | 68.6 | 354 | 77.6 | 292 | 60.1 | ||
pN | N0 | 567 | 60.2 | 269 | 59 | 298 | 61.3 | 0.589 |
N1 | 273 | 29 | 133 | 29.2 | 140 | 28.8 | ||
N2 | 102 | 10.8 | 54 | 11.8 | 48 | 9.9 | ||
PNI | Negative | 728 | 78.3 | 354 | 78.5 | 374 | 78.1 | 0.879 |
Positive | 202 | 21.7 | 97 | 21.5 | 105 | 21.9 | ||
LVI | Negative | 629 | 67.8 | 303 | 67.3 | 326 | 68.2 | 0.777 |
Positive | 299 | 32.2 | 147 | 32.7 | 152 | 31.8 | ||
Surgical margin | Negative | 928 | 98.5 | 449 | 98.5 | 479 | 98.6 | 0.096 |
Positive | 8 | 0.8 | 6 | 1.3 | 2 | 0.4 | ||
Adjuvant treatment | No | 208 | 22.1 | 94 | 20.6 | 114 | 23.5 | 0.293 |
Yes | 734 | 77.9 | 362 | 79.4 | 372 | 76.5 | ||
Adjuvant treatment regimen | 5-FU-based | 493 | 67.2 | 243 | 67.1 | 250 | 67.2 | 0.978 |
Oxaliplatin-based | 241 | 32.8 | 119 | 32.9 | 122 | 32.8 | ||
Completion rate of adjuvant treatment | 695 | 94.7 | 344 | 95 | 351 | 94.4 | 0.685 | |
Tumor recurrence | No | 804 | 85.4 | 389 | 85.3 | 415 | 85.4 | 0.971 |
Yes | 138 | 14.6 | 67 | 14.7 | 71 | 14.6 | ||
Locoregional recurrence | 40 | 29 | 21 | 31.3 | 19 | 26.8 | 0.553 | |
Systemic recurrence | 98 | 71 | 46 | 68.7 | 52 | 73.2 | ||
Metastasectomy | 48 | 34.8 | 24 | 35.8 | 24 | 33.8 | 0.804 | |
Status | Exitus | 95 | 9.1 | 51 | 11.2 | 44 | 9.1 | 0.278 |
Alive | 847 | 90.9 | 405 | 88.8 | 486 | 90.9 | ||
Median | Min-Max | Median | Min-Max | Median | Min-Max | |||
Age (yr) | 58 | 19-94 | 57 | 19-89 | 58 | 21-94 | 0.141 | |
Follow-up (mo) | 90 | 1-252 | 90 | 1-252 | 90 | 5-235 | ||
mean | SD | mean | SD | mean | SD | |||
Number of removed lymph nodes | 17.57 | 10.843 | 19.78 | 11.059 | 15.5 | 10.223 | < 0.001 | |
Number of metastatic lymph nodes | 1.46 | 4.068 | 1.41 | 2.86 | 1.5 | 4.944 | 0.743 |
- Citation: Sakin A, Arici S, Secmeler S, Can O, Geredeli C, Yasar N, Demir C, Demir OG, Cihan S. Prognostic significance of primary tumor localization in stage II and III colon cancer. World J Gastrointest Oncol 2018; 10(11): 410-420
- URL: https://www.wjgnet.com/1948-5204/full/v10/i11/410.htm
- DOI: https://dx.doi.org/10.4251/wjgo.v10.i11.410